Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02179749 · ClinicalTrials.gov registry record · Phase 2
Mifepristone Treatment of Alcohol Use Disorder
A Phase 2 study of Alcoholism and Alcohol Abuse, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT02179749: Completed Phase 2 study of Alcoholism and Alcohol Abuse, sponsored by The Scripps Research Institute.
NCT02179749 is a Phase 2 study of Alcoholism and Alcohol Abuse that has completed, run by The Scripps Research Institute. The registered enrollment target is 103 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02179749, a Phase 2 study of Alcoholism and Alcohol Abuse, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an 8-week, randomized, double-blind, placebo-controlled, 2 arm, parallel groups, study of 1-week of treatment with mifepristone (0, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.
Primary Outcome
Drinking quantity in standard drinks per day is measured by the Timeline Followback interview. A standard drink contains 14 grams of alcohol, e.g., 1.5 ounces of distilled spirits, 5 ounces of wine, or 12 ounces of beer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mifepristone 1200 mg daily
- BEHAVIORAL Standardized behavioral therapy
Study Locations (1)
California
- The Scripps Research Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-11-06 |
| Phase | Phase 2 |
What the finished NCT02179749 record still lists
NCT02179749 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (72% lower).
The record links to 4 conditions, with Alcoholism appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02179749 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02179749 about?
NCT02179749 is a clinical study titled "Mifepristone Treatment of Alcohol Use Disorder". This is an 8-week, randomized, double-blind, placebo-controlled, 2 arm, parallel groups, study of 1-week of treatment with mifepristone (0, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.
What is the current status of trial NCT02179749?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2014-09. Estimated completion is 2019-11-06.
What conditions does trial NCT02179749 study?
This clinical trial studies the following conditions: Alcoholism, Alcohol Abuse, Alcohol Dependence, Alcohol Use Disorders.
What interventions are being tested in trial NCT02179749?
The interventions under investigation include: Placebo (DRUG), Mifepristone 1200 mg daily (DRUG), Standardized behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02179749?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02179749 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02179749's enrollment target sits among peer trials
103 35th of 65 higher than 31 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia